Starna offers new photometric linearity reference sets

Published: 13-May-2010

Suitable for pharmaceutical QA laboratories

Starna offers new photometric linearity reference sets
Starna Scientific’s near infrared (NIR) traceable photometric linearity reference sets are now available for pharmaceutical QA labs and customer support organisations seeking to qualify their NIR systems. These reference sets offer Operational Qualification (OQ) and Performance Qualification (PQ) of the transmittance scale in the NIR using industry standard protocols.

The sets are based on easy to handle, non-consumable Certified Reference Materials for qualifying the NIR Transmittance scale. The wavelength range covered is 1100 to 2850nm, with a %T (A) range of 1.5 %T (1.82A) to 61%T (0.21A).

Starna, based in Hainault, Essex, UK, has many years of experience gained preparing Visible Neutral Density filter references for ISO 17025 and ISO Guide 34 accreditation and produces references for National Measurement Institutions (NMIs).

See more

You may also like

Manufacturing
Xelia and Hisun sign strategic global multiple-API partnership

Xelia and Hisun sign strategic global multiple-API partnership

Read more
Long-standing joint venture partners expand collaboration, moving beyond anti-infective APIs into diversified therapeutic areas, including cardiovascular and oncology

Trending Articles

  1. Loftware and RiseNow partner to strengthen supply chain traceability and compliance in healthcare settings The alliance pairs Loftware's SAP-integrated product identification platform with RiseNow's procurement and supply chain advisory services, delivering end-to-end track-and-trace capabilities for regulated industries where audit readiness and patient safety are critical
  2. Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T-cell engager The Swiss pharma company has agreed to pay $575m upfront for worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager targeting B-cell-driven autoimmune diseases
  3. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  4. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  5. Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif

You may also like

Manufacturing
Xelia and Hisun sign strategic global multiple-API partnership

Xelia and Hisun sign strategic global multiple-API partnership

Long-standing joint venture partners expand collaboration, moving beyond anti-infective APIs into diversified therapeutic areas, including cardiovascular and oncology
Research & Development
Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar introduces the new UNHT Series, a new generation of nanoindentation systems designed to deliver reliable results, faster workflows, and greater versatility across a wide range of materials
Ingredients
Indena to showcase its integrated European platform for HPAPIs and complex molecules at CPHI Milan 2026

Indena to showcase its integrated European platform for HPAPIs and complex molecules at CPHI Milan 2026

The leading unit CDMO will highlight breakthroughs in ADC payloads, ultra-high containment spray drying, and its strategic QS-21 partnership
Analysis
Cochrane review links pharma payments to prescribing practices

Cochrane review links pharma payments to prescribing practices

A Cochrane review of 93 studies has linked pharmaceutical industry promotional activities with less appropriate prescribing and higher prescription costs, prompting renewed calls for stronger conflict-of-interest policies and greater transparency in the UK
Research & Development
Rethinking the route to first-in-human studies

Rethinking the route to first-in-human studies

For sponsors, development activities and fragmented clinical supply can slow the path from candidate selection to first-in-human (FIH) dosing. A more integrated approach can reduce avoidable complexity while preserving the flexibility needed for early clinical programmes
Finance
Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network

Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network

The company has agreed to acquire New York-based Kinentia Biosciences, expanding its US presence and combining Kinentia’s early-stage development expertise with Ofichem’s European drug substance development and GMP manufacturing capabilities
Digital
Charles River and Autolomous launch Apollo Orchestrate LES to digitalise biologics QC testing workflow

Charles River and Autolomous launch Apollo Orchestrate LES to digitalise biologics QC testing workflow

The autoloMATE-powered platform connects sample submission, laboratory execution and review into a single digital workflow across Charles River's North American and European Biologics Testing Solutions sites — replacing paper-based processes to accelerate client results
Subscribe now